Harrow, a small biotech focused on ophthalmic pharmaceuticals, is rated a 'Strong Buy' with a fair value of $73.25, suggesting a 104% upside from its current price around $35.90. The positive outlook is driven by expected long-term growth from products like Vevye and Iheezo, along with other pipeline assets. Although recent short-term guidance was disappointing and market volatility remains, the analyst uses conservative financial models projecting strong EBIT margins and undervaluation even under risk scenarios. A combined strategy of shares and bullish short puts is recommended to optimize risk and reward given high implied volatility.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
Telo Genomics announced positive interim results from a clinical study analyzing blood samples of multiple myeloma patients to predict relapse risk using 3D telomere analysis. The test showed strong predictive accuracy, potentially offering a less in...
Meta now notifies parents if their teen talks about suicide or self-harm with its AI chatbot and is developing a feature to contact emergency services if risk is detected. This move addresses concerns about AI chatbots handling crisis conversations, ...
NTG Clarity Networks announced new purchase orders and contract renewals totaling about CAD 16.6 million, reflecting strong demand for its software development and digital transformation services. This includes $2.3 million from a real estate client ...
